Guardant Health (GH) Receives a Buy from Craig-Hallum
Craig-Hallum analyst William Bonello maintained a Buy rating on Guardant Health (GH – Research Report) today. The company's shares opened today at $38.45.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Bonello is a 4-star analyst with an average return of 8.3% and a 47.27% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Guardant Health, Veracyte, and GeneDx Holdings.
Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $60.00, representing a 56.05% upside. In a report released on May 16, Bank of America Securities also maintained a Buy rating on the stock with a $60.00 price target.
GH market cap is currently $4.73B and has a P/E ratio of -11.41.
Based on the recent corporate insider activity of 149 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year. Earlier this month, Tariq Musa, a Director at GH sold 116.00 shares for a total of $4,644.64.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Guardant Health's MCD test earns FDA breakthrough designation
Guardant Health's Shield multi-cancer detection (MCD) test has secured the US Food and Drug Administration's (FDA) breakthrough device designation. This methylation-based blood test is designed for the screening of various types of cancer in people who are 45 or above and are at a typical average cancer risk. The tested cancers include colorectal, oesophageal, bladder, gastric, lung, liver, pancreas, and ovarian. The FDA's designation for the MCD test follows its selection by the National Cancer Institute (NCI) for the Vanguard Study assessing the technology. This test was selected based on its predictive performance for cancer presence and for identifying the origin of the cancer tissue. At the 2025 American Society for Clinical Oncology Annual Meeting in Illinois, US, Guardant Health presented data from a case-control cohort of the Shield MCD test. The findings demonstrated the test's specificity and sensitivity, along with accuracy in determining the cancer signal of origin across various types of tumours. It exhibits 98.6% specificity and 75% sensitivity for detecting cancers, as per the data. The sensitivity range for individual cancers varied between 62% and 96%, with primary or secondary cancer signal origin accuracy reaching 92%. The breakthrough device designation is awarded to a select group of medical devices that show potential in treating or diagnosing life-threatening conditions compared to existing options. Guardant Health co-CEO and co-founder AmirAli Talasaz said: 'Every late-stage cancer we avert is a win for patients and for the entire healthcare system. 'This recognition by the FDA shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw. We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly.' Last year, the company expanded its market reach by striking a deal to promote its range of liquid and tissue biopsy tests for cancer screening in the Middle East and North Africa region. "Guardant Health's MCD test earns FDA breakthrough designation" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
4 hours ago
- Yahoo
3D Systems collaborates with Penn State, ASU researchers on NASA projects
3D Systems (DDD) is collaborating with researchers from Penn State University and Arizona State University on two projects sponsored by the National Aeronautics & Space Administration intended to enable ground-breaking alternatives to current thermal management solutions. Severe temperature fluctuations in space can damage sensitive spacecraft components, resulting in mission failure. By combining deep applications expertise with 3D Systems' leading additive manufacturing solutions comprising Direct Metal Printing technology and tailored materials and Oqton's 3DXpert software, the teams are engineering sophisticated thermal management solutions for the demands of next-generation satellites and space exploration. The project led by researchers with Penn State University, Arizona State University, and the NASA Glenn Research Center1 in collaboration with 3D Systems' Application Innovation Group has resulted in processes to build embedded high-temperature passive heat pipes in heat rejection radiators that are additively manufactured in titanium. These heat pipe radiators are 50% lighter per area with increased operating temperatures compared with current state-of-the-art radiators, allowing them to radiate heat more efficiently for high power systems. Additionally, a project led by researchers at Penn State University and NASA Glenn Research Center with 3D Systems' AIG yielded a process to additively manufacture one of the first functional parts using nickel titanium shape memory alloys that can be passively actuated and deployed when heated. This passive shape memory alloy radiator is projected to yield a deployed-to-stowed area ratio that is 6x larger than currently available solutions, enabling future high-power communications and science missions in restricted CubeSat volume. When deployed on spacecraft, such as satellites, these radiators can raise operating power levels and reduce thermal stress on sensitive components, preventing failures and prolonging satellite lifespan. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on DDD: Disclaimer & DisclosureReport an Issue 3D Systems Adjusts Equity Awards Amid Stockholder Meeting 3D Systems Corp Navigates Challenges with Strategic Focus 3D Systems Faces Persistent Revenue Challenges Despite Restructuring and Asset Sale, Justifying Hold Rating 3D Systems Reports Q1 2025 Financial Results 3D Systems' Financial Struggles Lead to Hold Rating Amid Revenue Declines and Withdrawn Guidance
Yahoo
4 hours ago
- Yahoo
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
Wells Fargo analyst Mohit Bansal notes that PTAB has instituted Merck's (MRK) patent grant review against Halozyme Therapeutics (HALO) MDASE patents. This patent is one of the patents Merck is fighting against Halozyme. The firm believes this likely reduces the probability of Halozyme prevailing in this case and weakens the bull argument. Wells has an Equal Weight on Halozyme with a price target of $65 on the shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on HALO: Disclaimer & DisclosureReport an Issue Merck granted review of Halozyme patent claims by PTAB Halozyme's Strategic Positioning and Market Potential Drive Buy Rating Halozyme announces EC approval of Bristol Myers' Opdivo developed with Enhanze Optimistic Buy Rating for Halozyme Amid Price Control Concerns Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
